Health
Interleukin-6 inhibitors appear to be a more effective treatment for COVID-19 – News-Medical.Net
New research from Boston Medical Center found that patients experiencing severe COVID-19 symptoms had improved outcomes when administered an Interleukin-6 (IL6ri) inhibitor, sarilumab or tocilizumab, given to mediate severe systemic inflammatory responses.
New research from Boston Medical Center found that patients experiencing severe COVID-19 symptoms had improved outcomes when administered an Interleukin-6 (IL6ri) inhibitor, sarilumab or tocilizumab, given to mediate severe systemic inflammatory responses.
The treatment was more effective when administered earlier in the disease course and reduced mortality rates and the need for intubation. Published in the International Journal of Infectious Diseases, the results show Interleukin-6 inhibitors…
-
Noosa News22 hours agoBrisbane’s Triffid forces redesign of $1.5 billion tower project
-
General18 hours agoIsraeli forces open fire towards diplomatic delegation touring Jenin in the northern West Bank
-
General11 hours agoCharlotte McConaghy calls for climate change action in new novel Wild Dark Shore
-
Business24 hours ago3 fantastic ASX ETFs to buy with $1,000